National Health Research Institutes

Academia Sinica

Industrial Technology Research Institute

Taivex Therapeutics Corporation

Weir-Torn Jiaang

Yu-Sheng Chao

Hsing-Pang Hsieh

Tsu Hsu

Chuan Shih

Tzu-Yu Lin

Tsu-An Hsu

Che-Kun James Shen

Shui-Tein Chen

Jui-Fa Chang

Tsing-Tang Song

Tsong-Shin Jean

Chih-Shin Chuang

Xin Chen

Su-Ying Wu

Chun-Ming Huang

Han-Bin Cheng

Wen-Hsing Lin

Ting-Yueh Tsai

Ping-Hui Tseng

Hui-Jen Tsai

Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein.

Compounds for uses in pharmacological induction of HBF for treatment of sickle cell disease and ß-thalassemia

Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: wherein Rand Rare defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.

Thiazole compounds as protein kinase inhibitors

Aminothiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the aminothiazole compounds.

Aminothiazole compounds as protein kinase inhibitors

Aminothiazole compounds of Formula (I) shown herein and pharmaceutical compositions containing one of such compounds.

Aminothiazole compounds

A compound of formula (I): wherein A, B, D, X, Y, R, R, R, m, p, and q are defined herein. Also disclosed is a method for inhibiting FMS-like tyrosine kinase 3, aurora kinase, or vascular endothelial growth factor receptor.

Pyrazole compounds and thiazole compounds as protein kinases inhibitors

Pyrrolidine compounds described herein and methods for using them to inhibit dipeptidyl peptidase IV and treat Type II diabetes.

Pyrrolidine derivatives

A compound of the following formula: wherein RR, R, R, R, R, W, X, Y, Z, m, n, and p are as defined herein. This invention also covers methods for inhibiting dipeptidyl peptidase IV or VIII, or treating Type II diabetes with such a compound.

Pyrrolidine compounds

A compound of the following formula: wherein R, R, R, R, R, R, R, R, T, X, Y, and Z are as defined herein. Also disclosed is a method for inhibiting dipeptidyl peptidase IV or for treating Type II diabetes with such a compound.

The present invention relates to a silicon-containing copolymer which includes a maleic anhydride repeating unit, a norbornene repeating unit, and at least one silicon group-containing norbornene repeating unit. The silicon-containing copolymer is suitable for use as a top layer resist in a bilayer resist system.

Silicon-containing copolymer and photosensitive resin composition containing the same

The present invention provides a novel method of synthesizing branched galactose-terminal glycoproteins. A number of these glycoproteins have binding affinity to the asialoglycoprotein receptor. The present invention also provides novel conjugates having branched galactose-terminal glycoproteins that is complexed to a therapeutically effective agent, such as an isolated protein, polysacharides, lipids and radioactive isotope. These conjugates may be used to deliver the therapeutically effective agent to mammalian cells generally, and to hepatocytes specifically.

Growing community of inventors

Taichung, Taiwan

Weir-Torn Jiaang